background
studi
suggest
intranas
vaccin
stimul
nonspecif
immun
agent
contain
within
vaccin
effect
report
cat
hypothesi
modifi
live
felin
felin
caliciviru
fcv
intranas
vaccin
reduc
clinic
sign
diseas
caus
experiment
infect
bordetella
bronchiseptica
anim
twenti
specif
pathogenfre
kitten
method
experiment
studi
cat
random
group
cat
vaccin
group
administ
singl
intranas
dose
commerci
avail
vaccin
contain
modifi
live
strain
fcv
control
group
remain
unvaccin
cat
administ
b
bronchiseptica
nasal
inocul
day
later
observ
daili
clinic
sign
ill
day
result
first
day
b
bronchiseptica
challeng
vaccin
cat
less
like
clinic
ill
control
cat
median
clinic
score
rang
versu
rang
p
nine
control
cat
vaccin
cat
record
sneez
day
challeng
p
conclus
clinic
import
intranas
vaccin
fcv
decreas
sign
ill
due
infecti
agent
contain
vaccin
nonspecif
immun
could
benefici
protect
organ
vaccin
avail
protect
develop
vaccineinduc
humor
immun
u
pper
respiratori
infect
one
common
syndrom
affect
cat
shelter
board
facil
multipl
cat
household
infecti
agent
implic
primari
caus
rhiniti
cat
includ
felin
herpesviru
felin
caliciviru
fcv
bordetella
bronchiseptica
chlamydophila
feli
mycoplasma
spp
strain
pasteurella
spp
vaccin
avail
fcv
b
bronchiseptica
c
feli
singl
product
avail
induc
protect
agent
addit
fcv
differ
strain
agent
respond
differ
vaccin
unlik
product
confer
complet
protect
differ
formul
respiratori
agent
contain
commerci
avail
vaccin
unit
state
major
avail
vaccin
formul
parenter
administr
howev
vaccin
contain
attenu
fcv
formul
intranas
administr
potenti
differ
immunolog
respons
induc
intranas
inocul
parenter
inocul
exampl
one
studi
intranas
administr
fcv
panleukopenia
fvrcp
vaccin
induc
rapid
serolog
respons
fcv
modifi
live
fvrcp
parenter
administr
studi
intranas
administr
fvrcp
vaccin
induc
protect
challeng
earli
day
singl
vaccin
administr
intranas
b
bronchiseptica
vaccin
induc
protect
b
bronchiseptica
earli
day
singl
vaccin
suggest
protect
mediat
least
part
nonspecif
immun
stimul
addit
intranas
administr
fvrcp
vaccin
induc
greater
lymphoblast
respons
concanavalin
nonspecif
mitogen
antigen
modifi
live
fvrcp
parenter
administr
c
therefor
seem
possibl
nonspecif
immun
stimul
induc
intranas
vaccin
might
lessen
clinic
sign
diseas
vaccin
expos
infecti
agent
contain
within
vaccin
case
murin
abbrevi
purpos
present
studi
investig
whether
intranas
administr
commerci
avail
vaccin
contain
fcv
confer
protect
intranas
challeng
infecti
agent
b
bronchiseptica
contain
vaccin
young
week
old
mix
sex
kitten
n
barrier
facil
known
neg
fcv
purchas
arriv
research
facil
sampl
collect
gentli
rub
steril
cotton
swab
oropharynx
level
molar
teeth
place
transport
media
cultur
aerob
bacteria
includ
b
bronchiseptica
mycoplasma
spp
e
total
dna
rna
extract
second
pharyng
swab
evalu
dna
dna
gapdh
control
dna
polymeras
chain
reaction
pcr
well
rna
fcv
revers
transcriptas
pcr
assay
previous
describ
vaccin
serum
collect
assay
fcv
antibodi
serum
neutral
f
kitten
test
chlamydophila
feli
kitten
random
util
random
number
gener
group
grouphous
differ
area
facil
acclimat
day
kitten
shown
neg
antibodi
fcv
neg
fcv
nucleic
acid
pharyng
swab
neg
b
bronchiseptica
cultur
one
group
administ
singl
dose
intranas
fvrc
vaccin
accord
manufactur
guidelin
day
group
vaccin
vaccin
facil
staff
member
use
barrier
precaut
avoid
crossinfect
kitten
modifi
live
vaccin
strain
fcv
protocol
approv
institut
anim
care
use
committe
research
facil
strain
b
bronchiseptica
grown
freez
solut
iowa
state
univers
success
cultur
isol
ship
overnight
colorado
state
univers
broth
subcultur
provid
adequ
challeng
inoculum
b
bronchiseptica
isol
subcultur
onto
tsa
tryptic
soy
agar
sheep
blood
agar
plate
ensur
organ
pure
cultur
pure
cultur
confirm
isol
put
ml
tsb
tryptic
soy
broth
allow
grow
hour
ambient
air
day
investig
ml
administ
ml
inoculum
nari
kitten
quantit
cultur
isol
perform
morn
challeng
inocul
show
approxim
cfu
b
bronchiseptica
administ
kitten
clinic
score
perform
daili
day
inocul
b
bronchiseptica
previous
design
upper
respiratori
diseas
score
system
g
adapt
appli
cat
daili
train
individu
blind
treatment
group
tabl
use
system
total
point
possibl
per
day
accordingli
total
point
possibl
studi
period
clinic
observ
spent
minut
cat
room
time
day
appli
clinic
score
paramet
kitten
includ
whether
sneez
observ
kitten
observ
period
aural
temperatur
collect
estim
chang
bodi
temperatur
reduc
stress
kitten
induc
repeat
rectal
temperatur
measur
h
aural
bodi
temperatur
accompani
lethargi
inappet
consid
evid
fever
day
b
bronchiseptica
challeng
pharyng
swab
collect
kitten
aerob
bacteri
cultur
mycoplasma
cultur
determin
whether
kitten
colon
b
bronchiseptica
inoculum
e
observ
period
divid
day
post
inocul
day
post
inocul
day
cumul
result
also
compar
group
total
clinic
score
vaccin
cat
compar
control
cat
within
observ
period
use
mannwhitney
utest
proport
individu
cat
observ
sneez
within
observ
period
compar
group
fisher
exact
test
lastli
percentag
total
observ
point
sneez
record
calcul
group
within
observ
period
cat
per
group
observ
point
per
day
period
compar
fisher
exact
test
signific
defin
p
analys
vaccin
b
bronchiseptica
inocul
kitten
neg
antibodi
fcv
neg
nucleic
acid
fcv
pharyng
swab
neg
b
bronchiseptica
mycoplasma
spp
pharyng
swab
cultur
day
b
bronchiseptica
inocul
cat
posit
b
bronchiseptica
cat
neg
mycoplasma
spp
cultur
one
b
bronchiseptica
neg
kitten
vaccin
cat
group
sneez
record
observ
facil
staff
member
equilibr
period
first
day
vaccin
inocul
b
bronchiseptica
clinic
sign
diseas
gener
mild
group
cat
sneez
predomin
clinic
sign
diseas
group
cat
aural
temperatur
rare
detect
none
cat
ever
consid
inappet
letharg
suggest
fever
occur
addit
ocular
manifest
diseas
uncommon
total
ocular
score
group
compar
statist
none
cat
develop
clinic
sign
sever
enough
requir
support
care
antibiot
therapi
control
cat
day
median
cumul
clinic
score
cat
b
bronchiseptica
challeng
possibl
point
rang
vaccin
cat
day
median
cumul
clinic
score
cat
rang
day
result
challeng
analyz
median
cumul
clinic
score
control
cat
possibl
point
rang
vaccin
cat
day
median
cumul
clinic
score
cat
rang
control
cat
significantli
higher
cumul
clinic
score
per
cat
vaccin
cat
day
observ
period
p
fig
overal
control
cat
vaccin
cat
sneez
least
observ
period
day
inocul
b
bronchiseptica
p
differ
group
longer
appar
day
control
cat
vaccin
cat
sneez
least
percentag
observ
point
sneez
record
fig
significantli
greater
control
cat
vaccin
cat
day
p
day
p
studi
cat
administ
singl
dose
modifi
life
fcv
vaccin
intranas
lower
total
clinic
score
control
cat
first
day
challeng
mildli
pathogen
strain
b
bronchiseptica
result
unlik
affect
prior
immun
infect
spf
kitten
use
infect
b
bronchiseptica
mycoplasma
spp
fcv
rule
neg
test
inocul
find
support
hypothesi
intranas
vaccin
fcv
confer
crossprotect
challeng
infecti
agent
b
bronchiseptica
contain
vaccin
howev
measur
effect
lost
second
day
observ
challeng
suggest
protect
shortliv
aforement
studi
efficaci
intranas
b
bronchiseptica
vaccin
rapid
protect
b
bronchiseptica
challeng
hour
vaccin
durat
immun
b
bronchiseptica
seem
plausibl
rapid
onset
protect
observ
nonspecif
immun
induc
process
intranas
vaccin
unintent
compon
vaccin
wherea
longer
term
protect
specif
acquir
immun
respons
b
bronchiseptica
base
current
studi
appear
vaccin
fcv
confer
longterm
durat
immun
organ
contain
within
vaccin
one
vaccin
cat
cultureneg
b
bronchiseptica
inocul
plausibl
cat
abl
clear
infect
possibl
assist
nonspecif
immun
confer
intranas
fcv
vaccin
howev
also
possibl
cultur
fals
neg
imperfect
sampl
cultur
techniqu
regardless
purposebr
spf
cat
age
hous
handl
ident
administ
standard
dose
inoculum
like
cat
expos
colon
b
bronchiseptica
accordingli
data
cat
includ
analysi
mechan
nonspecif
immun
induc
intranas
vaccin
fulli
understood
unknown
whether
infecti
agent
within
vaccin
compon
cell
cultur
protein
one
theori
prior
vaccin
might
dampen
cytokinemedi
inflamm
caus
respiratori
infect
lessen
clinic
sign
diseas
howev
studi
demonstr
crossprotect
effect
b
pertussi
vaccin
influenza
mice
effect
lag
least
week
behind
vaccin
mechan
seem
unlik
explan
find
describ
stimul
innat
immun
system
intranas
vaccin
seem
like
explan
rapid
boost
innat
immun
occur
administr
acnpv
chitin
microparticl
rodent
model
influenza
immun
effect
attribut
activ
natur
killer
cell
well
regul
inflammatori
cytokin
seem
plausibl
one
compon
innat
immun
system
natur
killer
cell
recruit
unrel
intranas
treatment
could
compon
innat
immun
system
would
protect
effect
bacteri
infect
immun
respons
kitten
measur
present
studi
research
requir
determin
mediat
nonspecif
immun
regardless
mechan
stimul
nonspecif
immun
via
intranas
vaccin
would
sever
benefit
first
might
provid
protect
organ
vaccin
avail
routin
administ
mycoplasma
spp
cat
dog
canin
herpesviru
canin
respiratori
coronaviru
canin
influenza
viru
dog
second
nonspecif
immun
like
becom
activ
specif
immun
still
develop
therebi
confer
protect
quickli
vaccin
b
bronchiseptica
challeng
studi
day
intranas
vaccin
fcv
time
onset
nonspecif
immun
respons
investig
previou
work
demonstr
partial
immun
respons
earli
day
intranas
vaccin
cat
type
earli
protect
would
particular
valu
event
unforeseen
exposur
potenti
infecti
organ
exampl
emerg
board
shelter
environ
typic
stray
hold
period
day
might
financi
limit
number
vaccin
administ
present
studi
limit
rel
mild
clinic
sign
observ
vaccin
control
cat
cat
studi
describ
administ
larger
dose
strain
b
bronchiseptica
administ
previou
studi
cat
studi
much
milder
clinic
sign
diseas
strain
b
bronchiseptica
studi
approxim
year
possibl
longterm
storag
multipl
passag
freez
thaw
agent
render
less
pathogen
addit
studi
describ
b
bronchiseptica
purpos
administ
cat
via
direct
inocul
rather
aerosol
avoid
need
sedat
attempt
minim
potenti
sever
system
ill
like
limit
inoculum
upper
respiratori
tissu
might
lessen
system
clinic
sign
diseas
like
fever
cough
final
studi
studi
crossprotect
effect
induc
one
vaccin
administ
intranas
whether
similar
effect
would
recogn
administr
intranas
vaccin
parenter
vaccin
unknown
research
area
warrant
